Clinical trial
The Safety and Efficacy of Recombinant Human Prolactin
NCT00438490 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00438490 |
|---|---|
| Title | The Safety and Efficacy of Recombinant Human Prolactin |
| Official title | Phase 2 Study of Recombinant Human Prolactin Efficacy and Safety |
| Lead sponsor | Massachusetts General Hospital, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Healthy |
| Intervention type | Drug |
| Interventions | Recombinant Human Prolactin |
| Enrollment | 21 |
| Start date | Apr 1, 2002 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Feb 22, 2007 |
| Last update posted | Jan 3, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: